Ask AI
ProCE Banner Activity

Comparison of Pharmacologic Properties of Approved PARP Inhibitors

Slideset Download
In this downloadable slideset, CCO’s expert faculty reviews pharmacologic properties of approved PARP inhibitors in newly diagnosed ovarian cancer.

Released: December 18, 2020

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany